Regeneron Pharmaceuticals | REGN - Sales Revenues


Regeneron Pharmaceuticals reported $4.29B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Agenus USD 33.7M 500K Mar/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Astellas Pharma JPY 537.93B 33.28B Mar/2026
AstraZeneca USD 15.38B 90M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Kyowa Hakko Kirin JPY 145.16B 26.69B Jun/2026
Merck USD 16.6B 310M Jun/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 15.03B 530M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026